We are live on ! Find out more
PC

Polar Capital Portfolio holdings

AUM $13.5B
1-Year Est. Return 55.9%
This Fund
S&P 500
This Quarter Est. Return
+34.87%
1 Year Est. Return
+55.9%
3 Year Est. Return
+127.44%
5 Year Est. Return
+269.08%
10 Year Est. Return
–
AUM
$11.6B
AUM Growth
+$2.27B
Cap. Flow
-$278M
Cap. Flow %
-2.4%
Top 10 Hldgs %
30.23%
Holding
354
New
65
Increased
75
Reduced
125
Closed
74

Top Buys

Rank Stock Value
1
UNH icon
UnitedHealth
UNH
+$106M
2
META icon
Meta Platforms (Facebook)
META
+$106M
3
PYPL icon
PayPal
PYPL
+$105M
4
XLNX
Xilinx Inc
XLNX
+$99.5M
5
CIEN icon
Ciena
CIEN
+$86.3M

Top Sells

Rank Stock Value
1
ABBV icon
AbbVie
ABBV
+$85.6M
2
BMY icon
Bristol-Myers Squibb
BMY
+$84.6M
3
AMZN icon
Amazon
AMZN
+$72.7M
4
INTC icon
Intel
INTC
+$72.2M
5
RNG icon
RingCentral
RNG
+$71.8M

Sector Composition

Rank Sector Weight
1 Technology 36.14%
2 Healthcare 19.11%
3 Financials 17.15%
4 Communication Services 12.94%
5 Consumer Discretionary 7.63%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
INSM icon
151
Insmed
INSM
$22.4B
$12.7M 0.11%
460,350
-39,650
-8% -$940K
KLIC icon
152
Kulicke & Soffa
KLIC
$4.34B
$12.2M 0.11%
+584,907
New +$13.2M
ACN icon
153
Accenture
ACN
$106B
$12.1M 0.1%
56,325
-56,509
-50% -$10.7M
CYTK icon
154
Cytokinetics
CYTK
$10.6B
$11.8M 0.1%
+500,000
New +$9.38M
AMG icon
155
Affiliated Managers Group
AMG
$9.51B
$11.7M 0.1%
156,854
-127,194
-45% -$8.6M
ALNY icon
156
Alnylam Pharmaceuticals
ALNY
$38.3B
$11.1M 0.1%
75,000
-75,000
-50% -$10.1M
AMGN icon
157
Amgen
AMGN
$209B
$11.1M 0.1%
+47,081
New +$10.7M
GBT
158
DELISTED
Global Blood Therapeutics, Inc.
GBT
$11M 0.1%
+175,000
New +$12M
SABR icon
159
Sabre
SABR
$716M
$11M 0.1%
+1,366,611
New +$9.69M
NBIX icon
160
Neurocrine Biosciences
NBIX
$18.2B
$11M 0.09%
89,878
-15,982
-15% -$1.77M
QURE icon
161
uniQure
QURE
$2.75B
$10.5M 0.09%
233,298
+29,800
+15% +$1.76M
VAR
162
DELISTED
Varian Medical Systems, Inc.
VAR
$10.4M 0.09%
85,012
-369,812
-81% -$42.8M
TSLA icon
163
Tesla
TSLA
$1.18T
$10.3M 0.09%
143,730
+57,135
+66% +$3.09M
PRA
164
DELISTED
ProAssurance
PRA
$10.1M 0.09%
700,000
– –
MYOK
165
DELISTED
MyoKardia, Inc. Common Stock
MYOK
$9.91M 0.09%
+102,585
New +$8.56M
LPSN icon
166
LivePerson
LPSN
$22M
$9.79M 0.08%
+15,748
New +$7.33M
MRTX
167
DELISTED
Mirati Therapeutics, Inc. Common Stock
MRTX
$9.7M 0.08%
85,000
-15,000
-15% -$1.45M
TEL icon
168
TE Connectivity
TEL
$60B
$9.45M 0.08%
+115,842
New +$8.72M
XLRN
169
DELISTED
Acceleron Pharma
XLRN
$9.34M 0.08%
98,078
+23,078
+31% +$2.22M
REPL icon
170
Replimune Group
REPL
$454M
$9.32M 0.08%
375,000
+125,000
+50% +$2.21M
DCPH
171
DELISTED
Deciphera Pharmaceuticals, Inc. Common Stock
DCPH
$8.96M 0.08%
150,000
-466,261
-76% -$24.9M
HCA icon
172
HCA Healthcare
HCA
$90.6B
$8.6M 0.07%
88,562
-444,865
-83% -$46.2M
BAND
173
Bandwidth Inc
BAND
$1.18B
$8.39M 0.07%
66,087
-17,093
-21% -$1.73M
TXN icon
174
Texas Instruments
TXN
$248B
$8.32M 0.07%
65,512
-119,261
-65% -$13.9M
APTO
175
DELISTED
Aptose Biosciences, Inc.
APTO
$8.06M 0.07%
2,840
-4,269
-60% -$13.8M
5 6
7
8 9

Similar funds

ECM
ETrade Capital Management Arlington, Virginia $5.37B AUM 10.84% 1-Year Est. Return
FAAS
First Allied Advisory Services San Diego, California $2.98B AUM 15.89% 1-Year Est. Return
WAM
Wealthspire Advisors (Maryland) Potomac, Maryland $2.84B AUM 10.91% 1-Year Est. Return
FS
Feinberg Stephen $2.61B AUM 15.12% 1-Year Est. Return
NIMC
NWQ Investment Management Company Los Angeles, California $2.22B AUM 6.84% 1-Year Est. Return
TI
TT International London, United Kingdom $1.94B AUM
VIM
Veritas Investment Management London, United Kingdom $1.65B AUM 25.54% 1-Year Est. Return
PS
Peter Svennilson $1.23B AUM 301.34% 1-Year Est. Return

Polar Capital's Q2 2020 Portfolio in Review

As of Q2 2020, Polar Capital held 354 positions worth $11.6B, up 24% from $9.31B the previous quarter. Its ten largest holdings account for 30% of the portfolio.

Polar Capital's Q2 2020 filing shows 65 new, 75 increased, 125 reduced and 74 closed positions. Its largest new stake was TripAdvisor: 3,886,053 shares worth $73.9M. The largest sale was AbbVie, an estimated $85.6M.

By sector, the portfolio is most concentrated in Technology at 36% of assets, up from 36% a quarter earlier, followed by Healthcare and Financials.

  • Polar Capital's largest Q2 2020 buy was TripAdvisor: 3,886,053 shares worth $73.9M.
  • Polar Capital added most to UnitedHealth in Q2 2020, an estimated $106M increase.
  • Polar Capital's biggest Q2 2020 reduction was Bristol-Myers Squibb, cutting an estimated $84.6M.
  • Polar Capital fully exited AbbVie in Q2 2020, selling an estimated $85.6M.
  • Polar Capital's ten largest holdings make up 30% of its $11.6B portfolio in Q2 2020.
  • Polar Capital opened 65 new positions and closed 74 in Q2 2020.
  • Polar Capital's portfolio value rose 24% quarter-over-quarter to $11.6B.

Based on Polar Capital's 13F filing for Q2 2020, filed 14 Aug 2020.